Share this article
Share this article
TORONTO, April 22, 2021 /CNW/ - Today, the Government of Canada and Uber Canada announced a partnership to help share critical information about COVID-19 vaccination with Canadians.
The Government of Canada and Uber Canada are partnering to help share critical information about COVID-19 vaccination with Canadians. (CNW Group/Uber Canada Inc.)
Health Canada and the Public Health Agency of Canada are collaborating with Uber to help inform Canadians about the safety and effectiveness of the authorized COVID-19 vaccines and the importance of continued adherence to public health measures. Through this initiative, users of the Uber app and drivers and merchants will receive information that will direct them to credible Government of Canada resources and information.
/PRNewswire/ Thomas Scientific, the largest pure-play distributor of scientific products in the US, has officially entered into a supplier partnership with.
Kodiak Sciences to Present at Upcoming Conferences
News provided by
Share this article
Share this article
PALO ALTO, Calif., April 21, 2021 /PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
Truist Securities 2021 Life Sciences Summit on Tuesday, May 4 at 8:20 a.m. Pacific Time (11:20 a.m. Eastern Time)
UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time)
A live webcast of both presentations will be available on the Events and Presentations section of Kodiak s website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
Share this article
Share this article
SHANGHAI, April 22, 2021 /PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that fail to respond to the standard therapy, has been accepted by the National Medical Products Administration (NMPA) and proposed to be granted priority review. Serplulimab is potentially to be the first anti-PD-1 mAb in MSI-H solid tumors in China. For this indication, patients are screened for specific MSI-H tumor markers, rather than classifying the tumor types, covering a wide range of cancer types. Henlius adopts the Combo+Global development strategy for serplulimab, focusing on indication differentiation and combination therapy, with a total of 10 clinical trials conducted worldwide.
BenefitMall Brings Industry Leading Sales Executive to Consumer Products Division, Expands Business Development Team
News provided by
Share this article
DALLAS, April 22, 2021 /PRNewswire/
BenefitMall, the leading provider of next-generation broker services, today announced the addition of Randal Mitchell to the Consumer Products Division as Sales Manager and the promotion of Alvin Sims to a Business Development Executive. As we continue to look for opportunities to enhance the services we provide for our brokers and their clients, we also must ensure we attract and retain high quality, talented executives that will help us be more innovative, forward thinking and solution oriented, said Roni Jernigan, Director of the Consumer Products Division at BenefitMall. We are excited to welcome Randal to the BenefitMall family as well as continue to foster Alvin s career growth within the organization.